For more information on drug pricing policy proposals, connect with us.
Find out the top 2020 healthcare trends to watch.
On May 11, the administration released “American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.” The blueprint highlights 4 key reform goals the administration may pursue to address the high cost of prescription drugs in the US: (1) improved competition, (2) better negotiation, (3) lower list prices, and (4) reduced out-of-pocket (OOP) costs. On May 14, HHS released a complementary request for information (RFI) soliciting input across the 4 priority areas.
The administration is approaching the issue of drug costs from a variety of angles, leveraging existing regulatory authority to advance smaller and more targeted changes in the near-term, while teeing up larger system reforms that may require future rulemaking or legislative action. HHS has opened a comment period through July 16 to allow stakeholder input on a series of complex operational and strategic issues and inform the agency’s next steps.
For example, the administration seeks feedback across select policy areas:
Outside of specific policy areas, HHS is also requesting input on the general structure and function of the pharmaceutical market. The broad nature of the RFI presents an important opportunity for stakeholders to engage on these topics and inform the administration’s strategy moving forward. In particular, the administration’s proposals present a host of operational and political considerations and may impact stakeholders differently.